Japan Digestive Disease Week 2025
International Poster Session7 (JDDW)
October 31, 10:42–11:14, Room 15 (Kobe International Exhibition Hall No.1 Building Digital Poster Venue)
IP-33_C
Hepatocellular Carcinoma and Secondary Colorectal Cancer: A Multi-Center Study in Taiwan
- 1
- Division of Gastroenterology and Hepatology, Department of Internal Medicine, Chi Mei Medical Center
- 2
- Department of Medical Research, Chi Mei Medical Center
Background and Objective:
This study investigated the incidence of secondary primary colorectal cancer (SPC-CRC) in hepatocellular carcinoma (HCC) patients and the impact of hepatitis B virus (HBV) infection on its development and prognosis. Data from our center (Yongkang and Liouying branches) were analyzed.
Methods:
A retrospective cohort study was conducted on HCC patients diagnosed between 2016 and 2022. Patients diagnosed with colorectal cancer as SPC-CRC were categorized into HBV-positive and HBV-negative groups after exclusion. Clinical characteristics, time to second cancer, treatment, and prognosis were compared.
Results:
A total of 3,545 patients were analyzed (1,913 from Yongkang, 1,632 from Liouying).
SPC-CRC incidence was 2.04% in Yongkang and 1.53% in Liouying.
Mean time to second cancer was 404.87 days (Yongkang) and 497.16 days (Liouying).
HBV infection did not significantly affect SPC-CRC incidence or survival (log-rank p=0.964).
Conclusion:
SPC-CRC occurred in about 2% of HCC patients, with no significant impact of HBV infection. Institutional differences may influence diagnosis timing. Long-term follow-up and further studies are needed to clarify risk factors.
This study investigated the incidence of secondary primary colorectal cancer (SPC-CRC) in hepatocellular carcinoma (HCC) patients and the impact of hepatitis B virus (HBV) infection on its development and prognosis. Data from our center (Yongkang and Liouying branches) were analyzed.
Methods:
A retrospective cohort study was conducted on HCC patients diagnosed between 2016 and 2022. Patients diagnosed with colorectal cancer as SPC-CRC were categorized into HBV-positive and HBV-negative groups after exclusion. Clinical characteristics, time to second cancer, treatment, and prognosis were compared.
Results:
A total of 3,545 patients were analyzed (1,913 from Yongkang, 1,632 from Liouying).
SPC-CRC incidence was 2.04% in Yongkang and 1.53% in Liouying.
Mean time to second cancer was 404.87 days (Yongkang) and 497.16 days (Liouying).
HBV infection did not significantly affect SPC-CRC incidence or survival (log-rank p=0.964).
Conclusion:
SPC-CRC occurred in about 2% of HCC patients, with no significant impact of HBV infection. Institutional differences may influence diagnosis timing. Long-term follow-up and further studies are needed to clarify risk factors.
- Index Term 1: Secondary Colorectal Cancer
- Index Term 2: Multi-Center Study